Bristol-Myers Squibb Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St · 08/02 12:31

Bristol-Myers Squibb (NYSE:BMY) Second Quarter 2025 Results

Key Financial Results

  • Revenue: US$12.3b (flat on 2Q 2024).
  • Net income: US$1.31b (down 22% from 2Q 2024).
  • Profit margin: 11% (down from 14% in 2Q 2024).
  • EPS: US$0.64 (down from US$0.83 in 2Q 2024).
earnings-and-revenue-growth
NYSE:BMY Earnings and Revenue Growth August 2nd 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Bristol-Myers Squibb Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 7.8%. Earnings per share (EPS) missed analyst estimates by 3.8%.

Looking ahead, revenue is expected to decline by 5.5% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 8.6%.

Performance of the American Pharmaceuticals industry.

The company's shares are down 8.7% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Bristol-Myers Squibb has 3 warning signs we think you should be aware of.